Daniela Katz

Mind the gap

[Daniela Katz @dkatz1370]

@schoffski Does the sponsor is running a trial in sarcoma?

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Check out this recent @ESMO_Open article on
circulating tumor DNA in neoadjuvant endocrine therapy for early #BreastCancer.
🔓https://t.co/qWcQiqowQ0
@elmayermd @nlinmd @stolaney1 @Otto_DFCI @RMJesel @DrEricWiner #ctDNA

[Daniela Katz @dkatz1370]

Real-World Outcomes of Immunotherapy Discontinuation at Two Years in Advanced Non-Small Cell Lung Cancer: final results of the ISTOP study. - European Journal of Cancer https://t.co/hkFum0f0V0

[Daniela Katz @dkatz1370]

@hoperugo @OncoAlert Almost all clinical trial require previous CDK4/6 treatment prior to enrolment.

[Patrick Schöffski @schoffski]

Serious drug-shortage issue for ifosfamide expected over the next few months due to manufacturing problems. This can have a major impact on the curative treatment of adult and paediatric patients with soft tissue sarcomas and Ewing family of tumours

[Dr Rishabh Jain @DrRishabhOnco]

🚨 New pooled safety data for T-DXd across DESTINY trials

Largest safety analysis to date of trastuzumab deruxtecan (T-DXd) across doses and tumor types is out in The Oncologist 🧬

🔍 What was analyzed
9 phase I-III DESTINY trials
N = 1,678 patients
Breast, gastric, lung cancers
Doses: 5.4 mg/kg vs 6.4 mg/kg Q3W

📊 Key safety signals
•Most common TEAEs: nausea, fatigue, neutropenia
•GI + hematologic toxicities dominate, mostly grade 1–2
•Dose modifications common, discontinuation relatively infrequent

🫁 ILD remains the key concern
•Adjudicated ILD: ~11–12% overall
•Grade ≥3 ILD: ~1.7–1.8%
•ILD-related mortality: ~1%
•Median onset: ~3–6 months → vigilance over time matters

👵 Who needs closer monitoring
•Age ≥65 years
•Renal impairment
•Longer treatment duration

💊 Practice-changing nuance
•NCCN now classifies T-DXd as highly emetogenic
•Proactive triple antiemetic strategies likely needed upfront

🧠 Bottom line
T-DXd toxicities are largely manageable, but require anticipation, early intervention, and structured monitoring, especially for ILD and nausea, to keep patients on this highly effective drug.

#OncoTwitter #MedTwitter #BreastCancer #HER2 #ADC #Enhertu

@DFCI_BreastOnc @stolaney1 @PTarantinoMD @OncoAlert @ASCO @myESMO @ESMO_Open

[Daniela Katz @dkatz1370]

@PTarantinoMD @TheLancetOncol Hyperglycemia?

[Brian Van Tine @bvantine1]

@APConley77 @MDAndersonNews @jalivingston_md @RavinRatan @NassifElise @GorlickRichard @JTrentMDPhD This picture documents a pivotal change in the field of #Sarcoma: amazing man, amazing impact, and in the picture is his amazing legacy

[Anthony P Conley @APConley77]

@NeetaSomaiahMD @vinodravi

[Daniela Katz @dkatz1370]

@Dr_R_Kurzrock Pectins

[Daniela Katz @dkatz1370]

@AnkitmanglaMD It is also a chemo-free option

[Daniela Katz @dkatz1370]

@DrHBurstein @NEJM @DanaFarber @DrMarkAwad @KevinHaigisLab I miss NEJM paper version

[Daniela Katz @dkatz1370]

@immunosarc @ctos @breelynwilkyMD What about YAP1-TFE3 any chance this fusion is also responsive to IO?

[Daniela Katz @dkatz1370]

@Sarcoma_UK @RobinL_Jones @royalmarsdenNHS @ICR_London Congrats! Wow!!!

[Daniela Katz @dkatz1370]

@JTrentMDPhD @SprakerMDPhD Not if disease is rapidly progressing

[Daniela Katz @dkatz1370]

@tmprowell @AC360 @CNN @KizzyPhD @drsanjaygupta Great point. I really “like” when I get an email Hello Daniela, Dr. said... the Dr. is always always a male.

[Anette Duensing @A_Duensing]

great opportunity for our #cancerresearch trainees - virtual annual @AACR 2020 meeting is free!

https://t.co/FeNffB3pEA

[Daniela Katz @dkatz1370]

@ASCO_pubs @JTrentMDPhD @WTapMD @SylvesterCancer Can the dose be increased?

[David Gandara @drgandara]

Sobering news. Publisher of hydroxychloroquine study says the research didn't meet its standards
https://t.co/Q5DLsh8gZk

[Toni Choueiri, MD @DrChoueiri]

#COVID19 course in 1 slide @OncoAlert